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of inflammatory cells, and increased apoptosis. 8 These defects tend to reduce aerobic capacity, which is manifested in the early onset of lactic acidosis. 9 Muscle fatigue occurs at work rates that would not engender fatigue in healthy subjects. It has been shown that in an appreciable fraction of patients with COPD, muscle fatigue rather than dyspnea is the primary factor limiting exercise tolerance. 10 It is likely that the primary cause of these muscle abnormalities is deconditioning 11 (patients with COPD are often very sedentary), but other COPD-specific factors probably contribute as well.
Pulmonary rehabilitation does not directly improve lung mechanics or gas exchange. 12 Rather, it optimizes the function of other body systems so that the effect of lung dysfunction is minimized 13 ( Fig. 1 ). High-intensity rehabilitative exercise programs improve muscle function by inducing chang es in muscle biochemistry. As a result, higher work rates can be tolerated without appreciable lactic acidosis. 9 For patients in whom ambulatory muscle dysfunction is a primary limitation, delayed fatigue directly enhances exercise tolerance. For patients in whom ventilatory limitation is primary, decreased lactic acidosis at a given level of exercise decreases ventilatory demand, probably by means of decreased carotidbody stimulation. 9 Dyspnea is also mitigated by reducing dynamic hyperinflation, which results when exercise leads to increased ventilatory demand and inadequate time is allowed for expiration, given the limitations on expiratory airflow. End-expiratory and, therefore, end-inspiratory lung volume is forced to increase progressively. When end-inspiratory lung volume approaches the limiting volume (total lung capacity), the elastic work of breathing and dyspnea increase markedly. Exercise training lowers ventilatory demand, resulting in a slowing of respiration at a given level of exercise. With a longer expiratory time there is less dynamic hyperinflation and, therefore, less dyspnea. 14 Pulmonary rehabilitation also works through other, less well-defined mechanisms. Exercise programs often result in desensitization to dyspnea (a decrease in the perception of dyspnea for a given task). 15 Factors hypothesized to contribute to this desensitization include the antidepressant effect of exercise as well as the social interaction and distraction from dyspneic sensations that occur during exercise with a group of patients who have the same condition. In addition, rehabilitation programs typically incorporate edu cation in the development of self-management strategies, an approach that involves a partnership between the patient and health professionals to system- Exercise training does not improve lung function, but it does ease other manifestations of COPD, increasing exercise tolerance, reducing dyspnea, and improving quality of life. Improved skeletal-muscle function is related, in part, to a reversal of deconditioning. Exercise training improves aerobic function of the muscles of ambulation. Dyspnea is mitigated by the reduction in dynamic hyperinflation that occurs when exerciseinduced increases in the rate and depth of breathing result in inadequate time for full expiration, given the high expiratory airflow resistance. End-expiratory lung volume rises, and exercise is terminated when endinspiratory lung volume approaches levels at which the high elastic work of breathing causes severe dyspnea. Exercise training reduces the ventilatory requirement and respiratory rate during heavy exercise, prolonging the time allowed for expiration and reducing dynamic hyperinflation. Desensitization to dyspnea occurs centrally as a result of exercise training; the underlying mechanism is uncertain. Decreased anxiety and depression are thought to result from increased exercise capacity and consequent increases in activities of daily living, coupled with feelings of mastery.
atically manage the symptoms of the disease. 16 This approach promotes adaptive behaviors, such as abstinence from smoking, better adherence to pharmacologic and exercise therapy, and earlier recognition and treatment of COPD exacerbations. Self-management education has been shown to reduce the use of health care services and costs among patients with moderate-to-severe COPD and a history of hospitalizations. 16, 17 Clinic a l Ev idence
Many clinical trials have examined the benefits of pulmonary rehabilitation, although virtually all of them were single-center trials of modest size. Demonstrations of benefit are based on randomized, controlled (though unblinded) studies. For three outcomes, the benefit is unequivocal 18 : exercise capacity (in incremental, constant work rate, and timed walking tests), severity of dyspnea, and health-related quality of life. For these three outcomes, the magnitude of benefit is generally superior to any other COPD therapy.
A recent meta-analysis by Lacasse et al. summarized 31 randomized, controlled trials of pulmonary rehabilitation. 19 In 11 trials involving 618 participants, health-related quality of life was evaluated with the use of the Chronic Respiratory Disease Questionnaire (CRQ). 20 Improvements were demonstrated in the four domains evaluated by this instrument: dyspnea, fatigue, emotional function, and mastery (the patient's feeling of control over the disease). The average effect size was 1.5 to 2.1 times the estimated minimum clinically important difference between the treatment and control groups. In 16 trials involving 669 participants, the weighted mean improvement in functional exercise capacity, assessed on the basis of the distance walked in 6 minutes, was 48 m. This approximated the estimated minimum clinically important difference of 50 m.
Individual studies of the effects of pulmonary rehabilitation have shown reductions in hospitalization and other measures of health care use 21, 22 and improvements in cost-effective ness. 23 Reductions in depression and anxiety and improvements in cognitive function and self-efficacy have been reported in trials specifically investigating these outcomes. 24 A survival benefit has not been demonstrated with pulmonary rehabilitation, although the randomized trials that have examined survival were relatively small and were underpowered to detect this effect. 18 
Clinic a l Use
The most common model for pulmonary rehabilitation in the United States is a multidisciplinary, hospital-based outpatient program, as originally developed and implemented by Petty et al. 25 Pulmonary rehabilitation is also provided in homebased, community-based, and inpatient settings. Program staffing varies but generally centers on a coordinator, who is typically trained in nursing, respiratory therapy, or physical therapy. The successful coordinator has excellent interpersonal skills, since (at least initially) a primary task is to motivate people to do what they may find unpleasant. Generally, a pulmonologist oversees the program.
Forced expiratory volume in 1 second (FEV 1 ) is not the sole criterion for selecting patients for pulmonary rehabilitation, 24 but patients who are typically referred for rehabilitation in the United States have stage 3 (severe) disease according to the four-stage Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification of severity (Table 1) . 2 However, those with milder disease may have distinct exercise intolerance that can be remediated with pulmonary rehabilitation. Patients whose disease is classified as stage 4 (very severe) may also be appropriate candidates, 26 although special efforts may be required to provide them with activities that are commensurate with their reduced exercise tolerance. Selection for pulmonary rehabilitation may also focus on patients whose dyspnea is out of proportion to the severity of their disease and on those for whom leg fatigue is the symptom that limits exercise tolerance. 27 In general, pulmonary rehabilitation is not recommended for patients who are unable to walk (because of orthopedic or neurologic disorders) or those with unstable cardiac disease (unstable angina or recent myocardial infarction). Other relative contraindications include cognitive or psychiatric problems that would prevent the patient from comprehending or cooperating with the treatment plan. Some programs exclude active smokers, although there are no convincing data that support this decision. 28 Many rehabilitation programs feature three directly supervised sessions per week, each lasting 3 to 4 hours. The duration of most programs ranges from 6 to 12 weeks, although some studies suggest that longer programs may provide additional and more durable benefits. 24 Program participation begins with clinical assessments by the medical director and rehabilitation coordinator, with reevaluation at intervals to gauge the patient's progress toward individualized exercise and educational goals. An argument can be made for an initial formal cardiopulmonary exercise test, 29 which provides information on the mechanism and severity of exercise intolerance, helps identify any cardiovascular or other contraindications to a rigorous exercise program, indicates whether there is a need for supplemental oxygen, and provides a guide for the intensity of the exercises prescribed.
The exercise program is the centerpiece of pulmonary rehabilitation. Endurance exercise of the leg muscles is the main focus, with walking, stationary cycling, and treadmill exercise commonly performed. High-intensity regimens are generally preferred, with initial targets of at least 60% of the maximum exercise tolerance, 13 although lower-intensity exercise is also beneficial. Exercise intensity is increased as tolerated under the observation of rehabilitation staff. A resistance-exercise component is also often included 18 ; improved leg strength aids in some activities of daily living and may lessen the risk of falls (although this benefit has yet to be demonstrated in clinical trials). Resistance training that involves the upper arms is also useful, 18 both because it facilitates the ability to carry out the activities of daily living and because some of the upper-arm muscles also serve as auxiliary muscles of respiration. 30 Respiratory-muscle training was once common, but it is now known that even with improvement of respiratory-muscle strength, functional capacity usually does not improve. 18 Ancillary measures have been added to the training routine to increase the intensity of exercise. In this regard, optimal bronchodilation during exercise sessions seems prudent. 31 The use of supplemental oxygen during training sessions, even in patients without substantial exercise desaturation, reduces ventilatory demand. 32 Other interventions that are being studied include the use of noninvasive ventilatory support, heliox (an inhaled mixture of helium and oxygen), ventilatory-pattern feedback, and anabolic steroids. 33, 34 Education is included in pulmonary rehabilitation to improve the patient's understanding of the disease and its treatment and to promote collaborative self-management strategies. [16] [17] [18] Examples of the latter include cessation of smoking, incorporation of exercise and increased physical activity in the home setting, promotion of the importance of adherence to therapy, and development of an action plan for earlier detection and treatment of COPD exacerbations. Since anxiety and depression are common in patients with COPD who are referred for pulmonary rehabilitation, many programs include a psychosocial component based on the needs of the individual patient.
Patients with COPD cachexia, characterized by involuntary weight loss and depletion of lean body mass, have a very poor prognosis. Nutritional supplementation is often offered to such patients, but this approach has had only limited efficacy in clinical trials. 35 The appetite stimulant megestrol acetate has been shown to increase body weight, but the weight gain typically consists of fat mass only. 36 Furthermore, overweight patients, as compared with those of normal weight, tend to have ventilatory limitation at low er exercise intensities because of the increased metabolic cost of activity. Weight-loss strategies are often recommended as part of pulmonary rehabilitation, although evidence of efficacy is lacking.
The increased exercise tolerance -and attendant benefits -gained during rehabilitation will recede within months after the program's end if patients resume their formerly sedentary lifestyle. Maintenance programs have been devised to help combat this tendency 37 ; these programs often include exercise classes that meet at regu- 1333 lar intervals. Many patients who complete pulmonary rehabilitation programs highly value the improvement in their condition and are successful in altering their lifestyle to maintain it, but reliable estimates of the percentage of participants who achieve this lifestyle alteration are not available. Currently, pulmonary rehabilitation programs are available for only a small fraction of patients with COPD who could potentially benefit from this approach; program availability is particularly problematic among lower-income, minority, and rural populations. A roadblock to achieving widespread availability in the United States has been the lack of a uniform funding policy. The cost of pulmonary rehabilitation has not been extensively documented; a recent report indicates that the average cost for a program with an average duration of 8 weeks in the National Emphysema Treatment Trial was about $2,200 per participant. 38 Reimbursement from third-party payers varies regionally. It is hoped that the recent passage of legislation designed to improve Medicare funding policy, to be implemented by January 2010, will increase access to pulmonary rehabilitation programs. 39
A dv er se Effec t s
No data from a registry of serious adverse events occurring during pulmonary rehabilitation have been published, but the widespread clinical impression is that these events are relatively rare. The principal risks of pulmonary rehabilitation programs are related to the exercise component of such programs. Musculoskeletal injury is a risk, since patients with COPD tend to be elderly and are often debilitated. This risk is reduced when rehabilitation is supervised by trained personnel. Exercise-induced bronchospasm occurs in some patients with COPD, and judicious use of bronchodilators before or during exercise may be appropriate. Perhaps the most important risk is that of a cardiovascular event (e.g., myocardial ischemia or infarction, arrhythmia, or even sudden cardiac death). Patients with COPD have a substantially increased risk of cardiovascular death, as compared with healthy age-matched controls. 40, 41 Before a patient starts an exercise program, evaluation for ischemic heart disease by means of a stress test is advisable.
A r e a s of Uncerta int y Most patients with COPD can benefit from a pulmonary rehabilitation program. Although some reports suggest that one quarter to one third of patients do not have a response to such a program, 42,43 the criteria for defining nonresponse have not been firmly established. Studies that have attempted to define subgroups of patients who will benefit from pulmonary rehabilitation have not identified any important predictors of a response to treatment. 42, 43 In cross-sectional studies, patients with COPD who have better exercise tolerance, less dyspnea, and lower rates of hospitalization have higher survival rates. [44] [45] [46] Since pulmonary rehabilitation provides these benefits, 18 it would be reasonable to suppose that it might impart a survival advantage. However, a randomized, adequately powered trial required to detect a modest (but clinically important) survival advantage has yet to be performed. 18, 47 Patients with high levels of physical activity have been found to use fewer health care resources and to have a lower risk of death, 48 making this a desirable goal in pulmonary rehabilitation. However, although re habilitation unequivocally increases exercise capacity, it is less clear whether this beneficial effect translates into increased daily physical ac tivity at home. Studies using activity monitors to evaluate the extent of patients' physical activity outside the study environment have had mixed results. [49] [50] [51] The benefits in exercise capacity and health status realized from pulmonary rehabilitation tend to decline in the months after the intervention. 18 Other than prolonging the formal program of pulmonary rehabilitation (which is not often feasible in the United States), it is unclear how best to maintain the benefits in the long term. Low-cost maintenance programs are a feature of many established rehabilitation programs. The self-management approach of incorporating exercise training in the home setting shows promise, but its benefits need to be confirmed.
Guidelines
Several documents summarize current knowledge regarding pulmonary rehabilitation practice: the American Thoracic Society-European 
R ecommendations
The patient in the vignette is an appropriate candidate for pulmonary rehabilitation, and we would recommend that she be enrolled in an outpatient, hospital-based program. Before she begins treatment, a stress test for cardiovascular evaluation, perhaps in the form of a cardiopulmonary exercise test, should be performed. Useful, but not mandatory, preprogram assessments include initial measurements of functional capacity (e.g., by means of a 6-minute walk test) and health-related quality of life (e.g., with the CRQ). She should then begin an 8-week program consisting of 24 sessions held for 3 hours each 3 times a week. In the exercise component of the program, we would include relatively high-intensity treadmill and stationary-cycle ergometer training as well as lower-intensity calisthenics. A self-management strategy for future COPD exacerbations should also be formulated, focusing on early recognition and treatment of exacerbations. At the end of the program, the 6-minute walk test and CRQ might be readministered and reassessed. After the patient has completed the formal program, we would strongly advise her to attend maintenance exercise sessions and to participate in a support group for patients with COPD.
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